10-Q: Immunome Q3 2025: Pipeline Advances Amid Rising R&D Costs

Immunome reports increased cash reserves and pipeline progress for Q3 2025, driven by financing activities and R&D investments, despite continued operating losses.

Summary

• Immunome ended Q3 2025 with $272.6 million in cash and cash equivalents, a significant increase from $143.4 million at December 31, 2024.
• The company reported a net loss of $57.5 million for the three months ended September 30, 2025, compared to $47.1 million for the same period in 2024.
• For the nine months ended September 30, 2025, the net loss was $142.5 million, an improvement from $212.7 million in the prior year, primarily due to lower in-process R&D expenses.
• Research and development expenses increased to $49.2 million for Q3 2025 (from $37.2 million in Q3 2024) and $126.5 million for the nine months (from $81.7 million in 9M 2024), reflecting increased investment in the pipeline.
• Collaboration revenue ceased in Q3 2025 following the termination of the agreement with AbbVie in July 2025.
• Varegacestat, a Phase 3 asset for desmoid tumors, is on track for topline data in H2 2025, having received Orphan Drug Designation from EMA in July 2025.
• IM-1021, a ROR1 ADC, is in an ongoing Phase 1 trial with objective responses observed in B-cell lymphomas; initial data expected in 2026.
• IM-3050, a FAP-targeted radioligand therapy, received IND clearance in April 2025, with a Phase 1 trial planned for early 2026.
• Preclinical ADC candidates (IM-1617, IM-1340, IM-1335) are advancing towards 2026 IND submissions.
• The company successfully raised $161.7 million net from a public offering in January 2025 and $44.9 million net from an ATM agreement in Q3 2025.
• Liquidity is projected to be sufficient for at least 12 months from the filing date.

Sentiment

Score: 5

Explanation: The company demonstrates strong liquidity from recent capital raises and significant pipeline progress with multiple clinical and preclinical assets advancing. However, this is balanced by increasing operating losses, a higher cash burn rate, and substantial shareholder dilution. The termination of the AbbVie collaboration also removes a revenue stream, highlighting the inherent risks in clinical-stage biotech.

Positives

• Cash and cash equivalents significantly increased to $272.6 million as of September 30, 2025, providing strong liquidity for at least 12 months.
• Net loss for the nine months ended September 30, 2025, decreased to $142.5 million from $212.7 million in the prior year, primarily due to lower IPR&D expenses.
• Varegacestat, a lead clinical asset, is progressing well in its Phase 3 trial, with topline data expected in the second half of 2025, and received Orphan Drug Designation from the EMA in July 2025.
• IM-1021, a ROR1 ADC, is showing objective responses in patients with B-cell lymphomas in its ongoing Phase 1 trial, with initial data anticipated in 2026.
• IM-3050, a FAP-targeted radioligand therapy, received IND clearance in April 2025, with a Phase 1 trial planned for early 2026, indicating pipeline advancement.
• Preclinical assets IM-1617, IM-1340, and IM-1335 are advancing towards 2026 IND submissions, demonstrating a robust early-stage pipeline.
• Successful capital raises through a public offering ($161.7 million net) and an At-The-Market (ATM) agreement ($44.9 million net in Q3 2025) have bolstered the company's financial position.
• Expanded office and laboratory space in Bothell, Washington, by 13,000 square feet in June 2025, supported by tenant improvement allowances of up to $9.3 million.

Negatives

• Net loss for the three months ended September 30, 2025, increased to $57.5 million from $47.1 million in the same period last year.
• Collaboration revenue ceased in Q3 2025 due to the termination of the agreement with AbbVie in July 2025, removing a previous revenue stream.
• Cash used in operating activities significantly increased to $143.0 million for the nine months ended September 30, 2025, compared to $68.7 million in the prior year, indicating a higher cash burn rate.
• Significant dilution of existing shareholders' ownership interest occurred due to the issuance of 22,258,064 shares in a public offering and 4,625,156 shares under the ATM agreement.
• General and administrative expenses increased by $1.4 million for Q3 2025 and $9.2 million for the nine months, primarily due to increased personnel-related costs and headcount.
• Interest income decreased by $0.7 million for Q3 2025 and $1.4 million for the nine months, primarily due to lower interest rates.
• The company will incur increased disclosure and compliance costs as it transitions from an emerging growth company to a non-accelerated filer and no longer a smaller reporting company by December 31, 2025.

Risks

• The company has a history of significant operating losses and expects to continue incurring losses for the foreseeable future, with no guarantee of achieving or maintaining profitability.
• There is inherent uncertainty in advancing product candidates through clinical development, obtaining regulatory approvals, and successfully commercializing them, with potential for significant delays.
• The IM-3050 program, as a targeted radioligand therapy, faces additional and potentially unpredictable challenges related to obtaining and delivering sufficient supply of raw materials and isotopes, finding suitable vendors, and limited sites for administration.
• Clinical trials are expensive, time-consuming, and difficult to design and implement, with preliminary results subject to change and earlier trial results not always predictive of future outcomes.
• The company may experience difficulties enrolling participants in its clinical trials, which could delay or adversely affect clinical development activities.
• Completion of clinical trials, particularly event-driven studies like varegacestat's RINGSIDE Part B, may experience delays as the timing of requisite events is unpredictable.
• The company faces substantial competition from other pharmaceutical and biotechnology companies, including those with greater financial resources and expertise, which could reduce or eliminate commercial opportunities.
• Undesirable side effects caused by any product candidates could lead to regulatory delays, denials, or withdrawals of approval, more restrictive labeling, or product liability claims.
• Reliance on third parties for manufacturing, supply, and testing, including sole-source vendors, poses risks of supply limitations, interruptions, or unsatisfactory quality.
• Protecting intellectual property (patents and trade secrets) is difficult and costly, with risks of patent invalidation, unenforceability, or challenges from third parties.
• The company's success depends on attracting and retaining qualified key management, technical personnel, and employees, and any inability to do so would impair its business plan.
• Unfavorable global economic and political conditions, including tariffs, trade barriers, and geopolitical conflicts, could adversely affect business, financial condition, or results of operations.
• The company is subject to significant product liability risks inherent in the development, testing, manufacturing, and marketing of antibody treatments, which may not be sufficiently covered by insurance.
• Cyber attacks or breaches of information technology systems or data, or those of third parties, could lead to regulatory actions, litigation, fines, business disruptions, and reputational harm.
• Concentration of laboratory operations in one location makes the company vulnerable to natural or other disasters, potentially disrupting business continuity.
• Compliance with stringent and evolving U.S. and foreign laws, regulations, and rules related to data privacy and security (e.g., HIPAA, GDPR, AI regulations) is complex and non-compliance could lead to significant penalties.
• Health care legislative reform measures, such as the Inflation Reduction Act of 2022 and the "One Big Beautiful Bill Act", may adversely affect the business by impacting drug pricing and reimbursement.
• Any product candidates approved as biologic products may face competition sooner than anticipated from biosimilar or generic products, potentially reducing market exclusivity.
• The company is subject to U.S. and foreign anti-corruption and anti-money laundering laws, with non-compliance potentially leading to criminal or civil liability.
• Future sales and issuances of common stock, including under equity incentive plans, could result in additional dilution of existing stockholders' percentage ownership.
• Changes in financial accounting standards or tax laws could adversely affect reported results of operations or financial condition.
• Inability to maintain an effective system of disclosure controls and internal control over financial reporting could impair the ability to produce timely and accurate financial statements.
• Significant costs are incurred as a result of operating as a public company, and management is required to devote substantial time to public company reporting and compliance initiatives.

Future Outlook

The company expects to continue incurring significant operating losses as it develops its therapeutic candidates. Existing cash and cash equivalents are projected to fund operations and capital expenditures for at least 12 months from the filing date. Future funding requirements will depend on the scope and progress of preclinical and clinical development, strategic transactions, intellectual property costs, regulatory review, and commercialization efforts. The company plans to initiate a Phase 1 trial for IM-3050 in early 2026 and expects to present initial data for IM-1021 in 2026. Preclinical assets IM-1617, IM-1340, and IM-1335 are targeting 2026 IND submissions. Topline data for varegacestat's Phase 3 trial is expected in the second half of 2025. The company will transition from an emerging growth company to a non-accelerated filer by December 31, 2025, leading to increased disclosure and compliance requirements.

Management Comments

• "We are a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients."
• "We believe that the pursuit of novel or underexplored targets will be central to the next generation of transformative therapies."
• "Our goal is to establish a broad pipeline of preclinical and clinical assets and develop these assets into approved products for commercialization."
• "We believe that IM-1021 may provide improved therapeutic index as compared to other ROR1-targeted ADCs in development."
• "We believe this RLT approach could overcome the limitations, such as poor internalization and low expression on tumor cells, that make FAP an unsuitable target for ADCs."
• "We believe that our teams ADC expertise positions us to develop the next generation of transformative ADCs."
• "We expect that our existing cash and cash equivalents at September 30, 2025 will be sufficient to fund our current and planned operating expenses and capital expenditures for at least 12 months from the filing date of this Quarterly Report on Form 10-Q."

Industry Context

Immunome operates in the highly competitive oncology sector, focusing on targeted therapies, including antibody-drug conjugates (ADCs) and radioligand therapies (RLTs). The company's strategy of pursuing novel or underexplored targets aligns with a broader industry trend seeking differentiated mechanisms of action to improve patient outcomes. The competitive landscape includes major pharmaceutical companies and other early-stage biotechs developing similar modalities. The termination of the AbbVie collaboration highlights the inherent risks and evolving nature of partnerships in drug discovery. The increasing R&D expenses reflect the high capital intensity of clinical-stage biotech, while successful capital raises demonstrate investor confidence in its pipeline and strategy, despite a challenging macroeconomic environment.

Comparison to Industry Standards

• Varegacestat (GSI for desmoid tumors) competes directly with SpringWorks Therapeutics' OGSIVEO (nirogacestat), which received FDA approval in November 2023. SpringWorks was acquired by Merck KGaA in July 2025, intensifying competition.
• IM-3050 (FAP-targeted RLT) faces competition from other companies developing FAP-targeted radioligand therapies, including Novartis, Yantai LNC Biotechnology, and Perspective Therapeutics, which have programs in clinical development.
• IM-1021 (ROR1 ADC) competes with other ROR1-targeting therapeutics, such as Merck's Zilovertamab vedotin (a ROR1 ADC in Phase 3 for diffuse large B-cell lymphoma) and CStone Pharmaceuticals' ROR1 ADC program.
• The company's IM-1335 ADC program is designed to optimize safety and efficacy compared to a competitor's now-discontinued investigational ADC targeting the same target, indicating an attempt to learn from prior industry failures.
• Immunome's focus on a proprietary TOP1i payload (HC74) and optimized linkers for its ADC platform aims to differentiate its candidates in a crowded ADC space, where several large pharmaceutical companies (e.g., Immunogen/AbbVie, AstraZeneca, Seagen/Pfizer) are actively investing.

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• May become involved in legal proceedings arising in the ordinary course of business from time to time.

Stakeholder Impact

• Shareholders: Experience significant dilution from recent and potential future equity offerings, but benefit from increased liquidity and pipeline advancement. Stock price volatility is expected.
• Employees: Increased headcount and personnel-related costs indicate growth in the workforce. Share-based compensation is a significant component of their remuneration.
• Customers (future): Potential for new targeted oncology therapies if product candidates achieve regulatory approval.
• Suppliers/Vendors: Continued reliance on third-party contract manufacturers, CROs, and other vendors for R&D and manufacturing, with risks related to supply chain and performance.
• Creditors: Improved cash position reduces immediate credit risk, but continued operating losses indicate long-term reliance on financing.

Next Steps

• Report topline data from the Phase 3 trial for varegacestat in the second half of 2025.
• Present initial data for IM-1021 in 2026.
• Initiate a Phase 1 trial for IM-3050 in early 2026, pending diagnostic radiotracer supply.
• Advance preclinical assets IM-1617, IM-1340, and IM-1335 towards 2026 IND submissions.
• Continue to invest in discovery efforts to expand the ADC pipeline.
• Manage increased disclosure and compliance requirements as the company transitions from an emerging growth company to a non-accelerated filer by December 31, 2025.
• Potentially raise additional capital through equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements beyond the next 12 months.

Key Dates

Recommendation

Immunome has significantly strengthened its cash position through recent capital raises, providing a runway for at least 12 months to advance its clinical pipeline. Key programs like varegacestat (Phase 3 with H2 2025 topline data), IM-1021 (Phase 1 with objective responses), and IM-3050 (IND cleared, Phase 1 early 2026) are progressing, which are crucial catalysts for a clinical-stage biotech. However, the company continues to incur substantial operating losses and has a high cash burn rate, which increased significantly year-over-year. The termination of the AbbVie collaboration removes a previous revenue stream. While pipeline progress is positive, the substantial dilution from recent equity offerings and the inherent high risks of drug development warrant a cautious approach. A "hold" recommendation reflects the balance between the company's improved financial stability and pipeline advancements against its continued unprofitability, high cash burn, and significant execution risks.

Keywords

Oncology, Biotechnology, Clinical-stage, Targeted therapies, Antibody-drug conjugate (ADC), Radioligand therapy (RLT), Varegacestat, IM-1021, IM-3050, Desmoid tumors, ROR1, FAP, Cancer treatment, Drug development, SEC filing, 10-Q, Financial results, Pipeline, Clinical trials, Preclinical, Capital raise, Liquidity, Research and development